GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • S. Karger AG  (3)
Material
Publisher
  • S. Karger AG  (3)
Person/Organisation
Language
Years
FID
  • 1
    Online Resource
    Online Resource
    Relationship of 〈b〉〈i〉CYP2C19*2 〈/i〉〈/b〉and 〈b〉〈i〉CYP2C19*3 〈/i〉〈/b〉Gene Polymorphism with Clopidogrel Response Variability and Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention
    S. Karger AG ; 2013
    In:  Pharmacology Vol. 91, No. 3-4 ( 2013), p. 165-172
    Details
    In: Pharmacology, S. Karger AG, Vol. 91, No. 3-4 ( 2013), p. 165-172
    Abstract: 〈 b 〉 〈 i 〉 Background/Aims: 〈 /i 〉 〈 /b 〉 The study was conducted to assess the influence of 〈 i 〉 CYP2C19 〈 /i 〉 polymorphisms on clopidogrel response variability and recurrent cardiovascular (CV) events in Chinese patients undergoing percutaneous coronary intervention (PCI). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Platelet aggregation induced by 5 and 20 µmol/l adenosine diphosphate was measured in 109 patients at baseline, 12 h and 36 h after loading with 300 mg of clopidogrel. The primary end point was recurrent CV events, and the follow-up was scheduled at 1, 3, 6 and 12 months after PCI. The polymorphisms of 〈 i 〉 CYP2C19*2 〈 /i 〉 and 〈 i 〉 CYP2C19*3 〈 /i 〉 were genotyped by DNA sequencing analysis 〈 i 〉 . 〈 /i 〉 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The maximal aggregation rates and inhibition of platelet aggregation among 〈 i 〉 CYP2C19*1/*1 〈 /i 〉 , 〈 i 〉 CYP2C19*1/*2 〈 /i 〉 or 〈 i 〉 *3 〈 /i 〉 and 〈 i 〉 CYP2C19*2/*2 〈 /i 〉 or 〈 i 〉 *3 〈 /i 〉 genotypes were significantly different at 12 and 36 h after clopidogrel loading dose administration. Multiple linear regression analysis demonstrated that 〈 i 〉 CYP2C19*2 〈 /i 〉 and 〈 i 〉 CYP2C19*3 〈 /i 〉 might be predictors of clopidogrel response variability. During the 12-month follow-up, recurrent CV events occurred in 21 (19.63%) patients, and there were 5 (6.47%) deaths, 3 (2.80%) cases of ischemic stroke and 14 (13.1%) cases of acute coronary syndrome. Carriers of at least one 〈 i 〉 CYP2C19 〈 /i 〉 loss-of-function allele ( 〈 i 〉 *1/*2 〈 /i 〉 or 〈 i 〉 *3, *2/*2 〈 /i 〉 or 〈 i 〉 *3 〈 /i 〉 ) incurred a 3.65-fold increase (95% CI 1.07–12.38; p = 0.038) in the risk of recurrent CV events 1 year after PCI compared to noncarriers ( 〈 i 〉 *1/*1 〈 /i 〉 ). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Polymorphisms in 〈 i 〉 CYP2C19*2 〈 /i 〉 and 〈 i 〉 CYP2C19*3 〈 /i 〉 contribute to variabilities in clopidogrel responsiveness. Patients carrying at least one 〈 i 〉 CYP2C19 〈 /i 〉 loss-of-function allele ( 〈 i 〉 CYP2C19*2, *3 〈 /i 〉 ) are associated with an increased risk of recurrent CV events undergoing PCI.
    Type of Medium: Online Resource
    ISSN: 0031-7012 , 1423-0313
    URL: Article
    DOI: 10.1159/000346736
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2013
    detail.hit.zdb_id: 1483550-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Role of Body Mass Index in Acute Kidney Injury Patients after Cardiac Surgery
    S. Karger AG ; 2018
    In:  Cardiorenal Medicine Vol. 8, No. 1 ( 2018), p. 9-17
    Details
    In: Cardiorenal Medicine, S. Karger AG, Vol. 8, No. 1 ( 2018), p. 9-17
    Abstract: 〈 b 〉 〈 i 〉 Background/Aims: 〈 /i 〉 〈 /b 〉 To explore the association of body mass index (BMI) with the risk of developing acute kidney injury after cardiac surgery (CS-AKI) and for AKI requiring renal replacement therapy (AKI-RRT) after cardiac surgery. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Clinical data of 8,455 patients undergoing cardiac surgery, including demographic preoperative, intraoperative, and postoperative data were collected. Patients were divided into underweight (BMI 〈 18.5), normal weight (18.5≤ BMI 〈 24), overweight (24≤ BMI 〈 28), and obese (BMI ≥28) groups. The influence of BMI on CS-AKI incidence, duration of hospital, and intensive care unit (ICU) stays as well as AKI-related mortality was analyzed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The mean age of the patients was 53.2 ± 13.9 years. The overall CS-AKI incidence was 33.8% ( 〈 i 〉 n 〈 /i 〉 = 2,855) with a hospital mortality of 5.4% ( 〈 i 〉 n 〈 /i 〉 = 154). The incidence of AKI-RRT was 5.2% ( 〈 i 〉 n 〈 /i 〉 = 148) with a mortality of 54.1% ( 〈 i 〉 n 〈 /i 〉 = 80). For underweight, normal weight, overweight, and obese cardiac surgery patients, the AKI incidences were 29.9, 31.0, 36.5, and 46.0%, respectively ( 〈 i 〉 p 〈 /i 〉 〈 0.001). The hospital mortality of AKI patients in the 4 groups was 9.5, 6.0, 3.8, and 4.3%, whereas the hospital mortality of AKI-RRT patients in the 4 groups was 69.2, 60.8, 36.4, and 58.8%, both significantly different ( 〈 i 〉 p 〈 /i 〉 〈 0.05). Hospital and ICU stay durations were not significantly different in the 4 BMI groups. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The hospital prognosis of AKI and AKI-RRT patients after cardiac surgery was best when their BMI was in the 24-28 range.
    Type of Medium: Online Resource
    ISSN: 1664-3828 , 1664-5502
    URL: Article
    DOI: 10.1159/000477824
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2018
    detail.hit.zdb_id: 2595659-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Prolonged Survival with Imatinib Mesylate Combined with Chemotherapy and Allogeneic Stem Cell Transplantation in de novo Ph+ Acute Myeloid Leukemia
    S. Karger AG ; 2012
    In:  Acta Haematologica Vol. 127, No. 3 ( 2012), p. 143-148
    Details
    In: Acta Haematologica, S. Karger AG, Vol. 127, No. 3 ( 2012), p. 143-148
    Abstract: 〈 i 〉 Background: 〈 /i 〉 De novo Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) is a rare disease with a poor prognosis. Imatinib mesylate (IM) is the standard treatment for Ph+ chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia; however, its role in Ph+ AML has not been extensively investigated. 〈 i 〉 Methods: 〈 /i 〉 Two patients aged of 46 and 19 years were diagnosed with de novo Ph+ AML according to the WHO Classification of Myeloid Neoplasms (2002) and the French-American-British (FAB) classification systems (1989). Cytogenetic analysis confirmed the presence of t(9;22). Standard RT-PCR was used to detect expression of the 〈 i 〉 BCR-ABL1 〈 /i 〉 fusion gene. Minimal residual disease was monitored by RQ-PCR for the 〈 i 〉 BCR-ABL1 〈 /i 〉 /ABL ratio. Both patients received initial IM therapy combined with daunorubicin-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) and IM maintenance treatment after allo-HSCT. 〈 i 〉 Results: 〈 /i 〉 Both patients achieved long-term disease-free survival with complete hematologic response, complete molecular response, and complete cytogenetic response for 44 and 48 months, respectively. 〈 i 〉 Conclusions: 〈 /i 〉 Our cases indicate that IM combined with daunorubicin-based chemotherapy followed by allo-HSCT and IM maintenance treatment is associated with a favorable outcome for de novo Ph+ AML, especially when IM is used in an early phase of AML.
    Type of Medium: Online Resource
    ISSN: 0001-5792 , 1421-9662
    URL: Article
    DOI: 10.1159/000334109
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2012
    detail.hit.zdb_id: 1481888-7
    detail.hit.zdb_id: 80008-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...